Literature DB >> 15570005

Application of a macromolecular contrast agent for detection of alterations of tumor vessel permeability induced by radiation.

Hisataka Kobayashi1, Koen Reijnders, Sean English, Alexander T Yordanov, Diane E Milenic, Anastasia L Sowers, Deborah Citrin, Murali C Krishna, Thomas A Waldmann, James B Mitchell, Martin W Brechbiel.   

Abstract

Permeability of tumor vasculature can be a major barrier to successful drug delivery, particularly for high molecular weight agents such as monoclonal antibodies and their diagnostic or therapeutic conjugates. In this study, changes in permeability of SCCVII tumor vessels after radiation treatment were evaluated by dynamic magnetic resonance imaging as a function of time after irradiation using a generation-8 polyamidoamine dendrimer (G8-Gd-D)-based magnetic resonance imaging contrast agent shown previously to be confined to tumor blood vessels. Tumor irradiation consisted of either single doses (2-15 Gy) or various daily fractionated doses (5 days). A single radiation dose of 15 Gy resulted in significant transient image enhancement of the tumor tissue with a maximum occurring between 7 and 24 hours after radiation treatment. No observable enhancement was recorded for fractionated radiation doses. Use of dynamic magnetic resonance imaging coupled with G8-Gd-D provides an exquisite methodology capable of defining the timing of enhanced permeability of macromolecules in tumors after irradiation. Such information might be applied to optimize the efficacy of subsequent or concurrent therapies including radiolabeled antibodies or other anticancer agents in combination with external beam therapies.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570005     DOI: 10.1158/1078-0432.CCR-04-1175

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

Review 1.  Overcoming the challenges in the effective delivery of chemotherapies to CNS solid tumors.

Authors:  Hemant Sarin
Journal:  Ther Deliv       Date:  2010-08

Review 2.  Biologically optimized nanosized molecules and particles: more than just size.

Authors:  Michelle R Longmire; Mikako Ogawa; Peter L Choyke; Hisataka Kobayashi
Journal:  Bioconjug Chem       Date:  2011-05-11       Impact factor: 4.774

3.  Molecular imaging using fluorescent lectins permits rapid endoscopic identification of dysplasia in Barrett's esophagus.

Authors:  Elizabeth L Bird-Lieberman; André A Neves; Pierre Lao-Sirieix; Maria O'Donovan; Marco Novelli; Laurence B Lovat; William S Eng; Lara K Mahal; Kevin M Brindle; Rebecca C Fitzgerald
Journal:  Nat Med       Date:  2012-01-15       Impact factor: 53.440

Review 4.  Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment.

Authors:  Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz
Journal:  Head Neck       Date:  2012-01-27       Impact factor: 3.147

Review 5.  Targeted alpha-therapy: past, present, future?

Authors:  Martin W Brechbiel
Journal:  Dalton Trans       Date:  2007-09-11       Impact factor: 4.390

6.  The selective hypoxia inducible factor-1 inhibitor PX-478 provides in vivo radiosensitization through tumor stromal effects.

Authors:  David L Schwartz; Garth Powis; Arun Thitai-Kumar; Yi He; James Bankson; Ryan Williams; Robert Lemos; Junghwan Oh; Andrei Volgin; Suren Soghomonyan; Ryuichi Nishii; Mian Alauddin; Uday Mukhopadhay; Zhenghong Peng; William Bornmann; Juri Gelovani
Journal:  Mol Cancer Ther       Date:  2009-04       Impact factor: 6.261

Review 7.  Perspectives: MRI of angiogenesis.

Authors:  Michal Neeman
Journal:  J Magn Reson       Date:  2018-04-12       Impact factor: 2.229

Review 8.  Imaging of Nanoparticle Distribution to Assess Treatments That Alter Delivery.

Authors:  Stephanie J Blocker; Anthony F Shields
Journal:  Mol Imaging Biol       Date:  2018-06       Impact factor: 3.488

9.  Improved micro-distribution of antibody-photon absorber conjugates after initial near infrared photoimmunotherapy (NIR-PIT).

Authors:  Tadanobu Nagaya; Yuko Nakamura; Kazuhide Sato; Toshiko Harada; Peter L Choyke; Hisataka Kobayashi
Journal:  J Control Release       Date:  2016-04-05       Impact factor: 9.776

Review 10.  Molecular imaging of EGFR/HER2 cancer biomarkers by protein MRI contrast agents.

Authors:  Jingjuan Qiao; Shenghui Xue; Fan Pu; Natalie White; Jie Jiang; Zhi-Ren Liu; Jenny J Yang
Journal:  J Biol Inorg Chem       Date:  2013-12-24       Impact factor: 3.358

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.